Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.to-BBB, the Dutch brain drug delivery company, has entered into a research collaboration with GlaxoSmithKline (GSK) involving to-BBB’s proprietary G-Technology in delivering a biological compound to the brain.
Subscribe to our email newsletter
As per the terms of the collaboration, to-BBB is expected to work with scientists at the GSK R&D centre in Shanghai, China, to further evaluate the brain delivery of treatments enhanced with to-BBB’s G-Technology.
G-Technology is designed to enhance transport of medicines across the blood-brain barrier by encapsulating these compounds into proprietary glutathione coated liposomes. The company has shown proof of concept in different disease models and GSK is expected to assess the technology with GSK nominated compounds.
Pieter Gaillard, CSO of to-BBB, said: “We look forward to working with the scientists at GSK R&D China. Combining the expertise of GSK in the area of neurobiology with to-BBB’s brain targeting knowledge, we hope will lead to advances in the treatment of diseases that affect the brain.”